Nomura/Instinet analyst, Christopher Marai, reiterated his Buy rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) after the company announced the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE